Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer

Figure 3

Kaplan-Meier survival curves according to miRNA-126 expression levels. (A) Illustrates the progression free survival (PFS) curves and (B) the overall survival (OS) curves. The yellow lines represent patients with high miRNA-126 expression levels and the blue lines patients with low miRNA-126 expression. The difference between the curves was significant in the PFS comparison, p < 0.0001, as well as in the OS comparison, p = 0.0021.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us